Report: VLST slashes workforce in shift to cancer drug research

Xconomy is reporting today that VLST is laying off two thirds of its staff in a cost-cutting move. CEO Martin Simonetti says that he's scaling down from 17 staffers to a virtual staff of 5 as funds are shifted to the development of a cancer drug recently in-licensed from Pfizer ($PFE). "We have very limited resources, and we had to make these extremely difficult decisions," he tells Xconomy. Story


Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.